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Small-Molecule Inhibitor of the Shigella flexneri Master Virulence
Regulator VirF
Veerendra Koppolu, Ichie Osaka, Jeff M. Skredenske, Bria Kettle, P. Scott Hefty, Jiaqin Li, Susan M. Egan
Department of Molecular Biosciences, University of Kansas, Lawrence, Kansas, USA
VirF is an AraC family transcriptional activator that is required for the expression of virulence genes associated with invasion
and cell-to-cell spread by Shigella flexneri, including multiple components of the type three secretion system (T3SS) machinery
and effectors. We tested a small-molecule compound, SE-1 (formerly designated OSSL_051168), which we had identified as an
effective inhibitor of the AraC family proteins RhaS and RhaR, for its ability to inhibit VirF. Cell-based reporter gene assays with
Escherichia coli and Shigella, as well as in vitro DNA binding assays with purified VirF, demonstrated that SE-1 inhibited DNA
binding and transcription activation (likely by blocking DNA binding) by VirF. Analysis of mRNA levels using real-time quanti-
tative reverse transcription-PCR (qRT-PCR) further demonstrated that SE-1 reduced the expression of the VirF-dependent viru-
lence genes icsA, virB, icsB, and ipaB in Shigella. We also performed eukaryotic cell invasion assays and found that SE-1 reduced
invasion by Shigella. The effect of SE-1 on invasion required preincubation of Shigella with SE-1, in agreement with the hypothe-
sis that SE-1 inhibited the expression of VirF-activated genes required for the formation of the T3SS apparatus and invasion. We
found that the same concentrations of SE-1 had no detectable effects on the growth or metabolism of the bacterial cells or the
eukaryotic host cells, respectively, indicating that the inhibition of invasion was not due to general toxicity. Overall, SE-1 ap-
pears to inhibit transcription activation by VirF, exhibits selectivity toward AraC family proteins, and has the potential to be
developed into a novel antibacterial agent.
Shigella is a major cause of bacillary dysentery (shigellosis) inhumans (1), a disease characterized by a short period of watery
diarrhea with intestinal cramps, followed by bloody mucoid
stools. Shigella is responsible for 165 million cases of illness and
more than 1.1 million deaths worldwide each year, and 70% of
those dying from illnesses due to Shigella are children under the
age of 5 (2, 3). Among Shigella species, Shigella flexneri causes
more mortality than any other; as few as 100 cells are sufficient to
cause disease (4). The first step in Shigella pathogenesis is invasion
of colonic and rectal epithelial cells. After invasion, Shigella repli-
cates and spreads from cell to cell within the colonic and rectal
epithelia. In addition to direct damage by Shigella, host inflamma-
tory responses also contribute to the epithelial cell damage leading
to shigellosis (5–12).
Given the enormous clinical relevance of Shigella infections, it
is important to find an effective treatment strategy to combat
them. Despite many efforts, no vaccine has been released for pub-
lic use, although a few vaccine candidates are currently in clinical
trials (13–16). A major obstacle to vaccine development is the
substantial heterogeneity of surface antigens among different
strains of this pathogen (1). Further, Shigella is rapidly developing
resistance to currently available antibiotics (17). In recent years,
the development of new antibiotics has generally been limited to
modifications of existing antibiotics (18–21), which primarily tar-
get essential bacterial proteins and put extensive selective pressure
on bacteria to develop resistance (22). In addition, broad-spec-
trum antibiotics adversely affect the resident gut microbiota (23).
Thus, new and innovative approaches are needed to circumvent
the problem of Shigella infections.
Anti-infective strategies that target several individual AraC
family bacterial virulence gene activator proteins have been re-
ported and have the potential to be developed into alternatives to
traditional antibiotics (24–28). AraC family proteins share se-
quence similarity in a region of approximately 100 amino acids
that functions as a DNA-binding domain (DBD) (29) and are
present in 70% of sequenced bacterial genomes (30). The DBDs of
AraC family proteins have two conserved helix-turn-helix motifs,
through which they bind to DNA and activate, or sometimes re-
press, transcription (29). AraC family proteins activate virulence
gene expression in many pathogenic bacteria, including Shigella
flexneri (VirF), Vibrio cholerae (ToxT), enterotoxigenic Esche-
richia coli (ETEC) (Rns/CfaD), and Pseudomonas aeruginosa
(ExsA) (29). Importantly, mutations that disrupt the function of
AraC family virulence activators reduce bacterial virulence with-
out affecting the growth of the bacteria (26, 31). Thus, inhibition
of AraC family virulence activators is expected to exert less selec-
tive pressure on bacteria to develop resistance than currently
available antibiotics (22, 32–34). Multiple lines of experimental
evidence indicate that targeting AraC family virulence activators
can dramatically reduce the severity of infections in animal mod-
els, suggesting that AraC family proteins may be excellent targets
for the development of novel antimicrobials (24–28).
The AraC family activator VirF is required for Shigella viru-
lence gene expression and is encoded on a 220-kb virulence plas-
mid (35). VirF expression has been shown to be temperature de-
pendent, with 3- to 4-fold-lower expression at 30°C than at 37°C
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(36, 37). The nucleoid-associated protein H-NS represses VirF
expression at 30°C by binding to sites within an intrinsically
curved region of the virF promoter (38, 39). At 37°C, a change in
DNA structure results in the release of H-NS from DNA, thereby
facilitating VirF expression (36, 38, 40, 41).
VirF activates the expression of a cascade of genes responsible
for the formation of the type three secretion system (T3SS) ma-
chinery, the invasion of host epithelial cells by Shigella, and cell-
to-cell spread (5–8, 42). VirF directly activates the expression of
the icsA and virB virulence genes (43, 44). The icsA gene encodes
the IcsA (VirG) protein, which aids the intracellular movement
of the pathogen by mediating actin-based motility (45–48). The
virB gene encodes a transcriptional activator, VirB, which in turn
activates the expression of many virulence-associated genes (in-
cluding the mxi, spa, and ipa operons) (37). virB expression is also
regulated by H-NS and thus has VirF-dependent and VirF-inde-
pendent mechanisms that increase its expression at 37°C over that
at 30°C (11, 49). Genes in the mxi and spa operons encode the
T3SS machinery, through which effectors are released into host
cells (50). Genes in the ipa operon encode effector proteins (IcsB,
IpaA, IpaB, IpaC, and IpaD) that translocate directly into host
cells. Among the effectors, IpaB plays major roles in the formation
of pores in the host cell membrane, the lysis of phagosomes, and
macrophage apoptosis (7, 51–54). Another effector, IcsB, prevents
the triggering of host autophagy, a process that can be used by host
cells to export invading bacteria to lysosomes for degradation (55,
56). Given that VirF is required for VirB expression and that VirB
activates the expression of multiple virulence-associated genes
that are required for the earliest steps in the successful invasion of
host cells by Shigella, VirF is considered the master regulator of
Shigella virulence (5–8, 42). Shigella mutants that do not express
VirF are avirulent but grow at the same rate as the wild-type bac-
teria (57, 58). We therefore reasoned, as have others (59), that
VirF has potential as a target for novel antibacterial agents and that
its nonessential nature has the potential to reduce the develop-
ment of resistance.
We recently identified an AraC family inhibitor, SE-1 (for-
merly called OSSL_051168), that selectively inhibited two AraC
family activators, RhaS and RhaR, despite their limited sequence
similarity with each other (60). We further found that SE-1 inhib-
ited RhaS and the RhaS DNA-binding domain (RhaS-DBD) to the
same extent and that it blocked DNA binding by RhaS and RhaR
(60). Furthermore, SE-1 had little or no impact on DNA binding
by the non-AraC family proteins LacI and cyclic AMP receptor
protein (CRP), indicating selectivity for at least the AraC family
proteins tested (60). Taken together, our results support the hy-
pothesis that SE-1 acts on the RhaS and RhaR DBDs—the struc-
turally conserved domain in AraC family proteins (29, 60). These
observations lead us to propose the hypothesis that this com-
pound might selectively inhibit additional AraC family activators.
Here we have tested the ability of SE-1 to inhibit another AraC
family activator, the master Shigella virulence activator VirF. Our
results showed that the compound effectively inhibited the bind-
ing of VirF to DNA and therefore its ability to activate transcrip-
tion in vivo. Analysis of mRNA levels for direct and indirect targets
of VirF showed a significant reduction in the level of expression of
these genes in the presence of SE-1. SE-1 also demonstrated sig-
nificant inhibition of invasion of epithelial cells in tissue culture by
Shigella without showing any detrimental effects on the growth of
the bacterial cells or the metabolism of the host cells. We hypoth-
esize that the reductions in the levels of gene expression and inva-
sion are due to inhibition of VirF activity by SE-1. Overall, we have
demonstrated that SE-1 inhibits transcription activation by the
Shigella master virulence regulator, VirF.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. The bacterial strains
and plasmids used in this study are shown in Table 1. Escherichia coli
strains were grown in tryptone-yeast extract (TY) broth (0.8% Difco tryp-
tone, 0.5% Difco yeast extract, and 0.5% NaCl [pH 7.0]). Cultures for
phage P1vir infection (generalized transduction) were grown in TY broth
supplemented with 5 mM CaCl2. Difco nutrient agar (1.5% agar) (Becton
Dickinson and Company [BD], Cockeysville, MD) was used routinely to
grow E. coli strains on solid medium. S. flexneri was cultured in tryptic soy
broth (TSB; pH 7.0) (BD) or Luria-Bertani broth (1% tryptone, 0.5%
yeast extract, and 1% NaCl) or on tryptic soy agar (TSA; 1.5% agar) (BD)
containing Congo red dye (0.025%). All Shigella strains were picked as red
colonies from TSA plates containing Congo red. Cultures were grown at
37°C unless otherwise specified. Appropriate antibiotics (ampicillin, 100
g/ml; tetracycline, 20 g/ml; chloramphenicol, 30 g/ml; gentamicin,
10 g/ml) were used as indicated. The entire open reading frames of all
cloned genes were sequenced on both strands. L-929 mouse fibroblasts
(ATCC, Manassas, VA) were routinely cultured in RPMI 1640 tissue cul-
ture medium (Mediatech, Manassas, VA) supplemented with 10 g/ml
gentamicin (MP Biomedicals, Santa Ana, CA) and 5% fetal bovine serum
(FBS; Thermo Fisher, Waltham, MA) in a humidified 5% CO2 incubator
at 37°C.
Construction of strains for in vivo dose-response studies. For dose-
response studies, a virB-lacZ reporter strain that allowed isopropyl--
D-thiogalactopyranoside (IPTG)-induced expression of VirF from
plasmid pHG165 was constructed (61). To construct this virB-lacZ
reporter strain, MAD102 was isolated from strain AB97 and was used
to infect strain ECL116 (62), and single-copy lysogens were identified
(63–65). P1vir-mediated generalized transductions were then used to add
malP::lacIq and recA::cat to this strain, as described previously (60, 66).
The virF gene was amplified (forward oligonucleotide, 5=-GATGAATTC
TAAATATAGTTTGGTTATTCTGTTGAATTTATG-3=; reverse oligo-
nucleotide, 5=-GTGCTGCAGTTAAAATTTTTTATGATATAAGTAAAA
TTTCTTTGGAG-3=), digested with EcoRI and PstI, and then ligated into
the same sites of plasmid pHG165. The resulting plasmid, pHG165virF,
was transformed into SME4259 to make SME4382 (see Fig. S1 [top] in the
supplemental material). A control strain, SME3359, which carries a sin-
gle-copy hts-lacZ reporter fusion in the chromosome and plasmid
pHG165lacI, expressing LacI protein (see Fig. S1, bottom), was con-
structed as described previously (60). Briefly, the hts-lacZ reporter fusion
consists of a synthetic promoter that is repressed by LacI. The control
strain is isogenic with SME4382, except that it does not carry malP::lacIq,
and therefore, LacI is expressed from pHG165lacI regardless of the pres-
ence of IPTG.
In vivo dose-response experiments with E. coli. In vivo dose-re-
sponse assays were performed using a procedure described previously (60).
In brief, cultures of SME4382 and SME3359 grown overnight were diluted to
an optical density at 600 nm (OD600) of 0.1. SE-1 (1-butyl-4-nitromethyl-
3-quinolin-2-yl-4H-quinoline; formerly designated OSSL_051168) was
obtained from eMolecules, Inc., Solana Beach, CA (catalog no. 3761-
0013), or Princeton BioMolecular Research, Princeton, NJ (catalog no.
OSSL_051168) (Fig. 1A), and was dissolved in 100% dimethyl sulfoxide
(DMSO). Bacterial cultures were mixed with varying concentrations of
SE-1 (final concentration of DMSO, 2.2%), induced with 6.5 mM IPTG
for 3 h at 37°C, and then lysed, and -galactosidase activity was measured
(60). Uninduced (no IPTG and no SE-1) and uninhibited (6.5 mM IPTG
and no SE-1) controls were included for each strain and were used to
normalize -galactosidase activity, as described previously (60). Fifty per-
cent inhibitory concentrations (IC50s) were calculated, and graphs were
drawn, using GraphPad Prism (GraphPad, La Jolla, CA). Error bars in
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figures represent the standard errors of the means for three independent
experiments with two replicates each.
E. coli growth curves. To test the impact of SE-1 on the growth of the
bacterial strains used for in vivo dose-response assays (SME4382 and
SME3359), we compared growth rates in the presence and absence of SE-1
by using a procedure described previously (60), but without the addition
of rhamnose. Briefly, the cells were grown at 37°C with shaking in mor-
pholinepropanesulfonic acid (MOPS)-buffered minimal medium with
glycerol plus 6.5 mM IPTG, in 24-well plates, either with SE-1 (44 M
SE-1, 0.3% DMSO) or with DMSO (0.3%) alone, in a PowerWave XS
plate reader equipped with KC4 data analysis software (BioTek Instru-
ments).
Heterologous expression and purification of VirF. The IPTG-induc-
ible MBP-VirF expression plasmid pMALvirF was constructed by cloning
virF downstream and in frame with malE (encoding maltose binding pro-
tein [MBP]) in the pMAL-c2X vector (New England BioLabs, Beverly,
MA). MBP-VirF protein (referred to below as VirF for simplicity) was
purified using amylose affinity chromatography at 4°C. Briefly, pMALvirF
was transformed into E. coli strain KS1000 (New England BioLabs). The
cells were grown to an OD600 of 0.5 and were transferred to 15°C; 0.1 mM
IPTG was added; and the cells were then incubated overnight with shak-
ing. Cells were harvested and resuspended in 10 ml of binding buffer (20
mM Tris, 500 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol [DTT] [pH
7.4]). Cells were lysed by three freeze-thaw cycles with lysozyme (0.4 mg/
ml), tris(2-carboxyethyl)phosphine (TCEP; 1 mM), and phenylmethyl-
sulfonyl fluoride (PMSF; 1 mM) at 80°C, followed by sonication, and
were then centrifuged to remove cell debris. The supernatant was applied
to an amylose resin column using a BioLogic low-pressure (LP) chroma-
tography system (both from Bio-Rad Laboratories). The column was pre-
equilibrated with 80 ml binding buffer and was then washed with 120 ml
binding buffer. VirF was eluted with 40 ml of elution buffer (binding
buffer plus 15% [wt/vol] glycerol and 10 mM maltose) and was used
directly for subsequent assays. The purified protein was more than 90%
TABLE 1 Bacterial strains and plasmids used in this study
Strain or plasmid Genotype or relevant characteristicsb Source or reference
Strains
E. coli strains
AB97 MC4100 MAD102 [(virB-lacZ)]a A. Maurelli
SME4021 ECL116 MAD102 [(virB-lacZ)]a This study
SME4240 SME4021 malP::lacIq zhc-511:: Tn10 This study
SME4259 SME4240 recA::cat This study
SME4382 SME4259  pHG165virF This study
ECL116 F lacU169 endA hsdR thi 62
SME1048 ECL116 recA::cat Laboratory collection
MC4100 F araD139 (argF-lac)U169 rpsL150 relA1 flhD5301 deoC1 ptsF25 rbsR 97
SG22166 MC4100 malP::lacIq ftsH1(Ts) zgj::Tn10 66
SME3358 ECL116 rhaS  (Phts-lacZ) recA::cat This study
SME3359 SME3358  pHG165lacI This study
SME4319 KS1000  pMAL virF This study
KS1000 F= lacIq lac pro ara (lac-pro) (tsp) (prc)::Kanr eda51::Tn10 Tetr gyrA (Nalr) rpoB thi-1 argE(Am) 98
Shigella strains
SME4331 S. flexneri ipgD W. D. Picking
SB116 S. flexneri mxiH 6
BS536 S. flexneri virB-lacZ A. Maurelli
Plasmids
pHG165 lacZ	 rop Ampr; essentially pUC8 with pBR322 copy number 61
pHG165virF This study
pHG165lacI This study
pMAL-c2 lacIq malE-lacZ	; Ampr New England BioLabs
pMAL virF This study
a The virB promoter portion of the fusion comprised nucleotides 259 to 308 relative to the transcription start site (1).
b Kanr, kanamycin resistant; Nalr, nalidixic acid resistant; Ampr, ampicillin resistant.
FIG 1 Chemical structure of SE-1 and inhibition of in vivo VirF activation in E.
coli. (A) Chemical structure of SE-1 (1-butyl-4-nitromethyl-3-quinolin-2-yl-4H-
quinoline). (B) -Galactosidase (LacZ) activities from two reporter fusions in E.
coli, VirF-activated virB-lacZ (SME4382) (circles) and LacI-repressed hts-lacZ
(SME3359) (triangles), were assayed at the indicated concentrations of the inhib-
itor SE-1. VirF and LacI were each expressed from plasmid pHG165. Activity in the
absence of SE-1 was set to 100% in each case and corresponded to approximately
950 Miller units for virB-lacZ and 350 Miller units for hts-lacZ. Results are averages
for three independent experiments with two replicates each.
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pure (see Fig. S2 in the supplemental material), although some older prep-
arations showed partial breakdown to MBP and nonfused VirF. Electro-
phoretic mobility shift assays (EMSAs) showed no evidence of nonfused
VirF binding to DNA (data not shown), suggesting that the nonfused VirF
protein was inactive (likely due to aggregation).
EMSAs. The binding of purified VirF to a DNA fragment containing the
VirF binding site at virB was analyzed by EMSAs (67) in the absence or pres-
ence of SE-1. DNA probes were generated by hybridizing (68) the following
oligonucleotides (Eurofins MWG Operon, Huntsville, AL): a short IR700-
labeled LUEGO (labeled universal electrophoretic gel shift oligonucleotide)
(5=-GTGCCCTGGTCTGG-3=) (68), a top oligonucleotide containing the
virB binding sites (underlined in sequences) (5=-AGAATATTATTCTTTT
ATCCAATAAAGATAAATTGCATCAATCCAGCTATTAAAATAGTA-
3=), and a bottom oligonucleotide that was complementary to both of the
preceding oligonucleotides (5=-TACTATTTTAATAGCTGGATTGATG
CAATTTATCTTTATTGGATAAAAGAATAATATTCT CCAGACCAG
GGCAC-3=). Reactions and electrophoresis were performed as described
previously (60) but without any of the additives described; however, all
reaction mixtures contained 10% DMSO (used to dilute SE-1). Gels were
scanned using an Odyssey infrared imager (Li-Cor, Lincoln, NE) and were
quantified using Odyssey software, version 3.0.30. Graphs were drawn
using GraphPad Prism (GraphPad).
Fluorescence-based thermal shift assay. Binding of SE-1 to purified
VirF was tested by comparing the VirF melting temperature (Tm) in the
absence of SE-1 to that in its presence using a thermal shift assay with the
fluorescent dye Sypro Orange (69, 70) (Molecular Probes). This method is
also known as differential scanning fluorimetry (DSF) (71). We used the
protocol of Ericsson et al. (70) with the following minor modifications. As
a control, we tested the binding of SE-1 to the unrelated purified protein
MBP-NS1-NTD (more than 95% pure). Reaction mixtures contained the
following (final concentrations): 1 M protein, 20
 Sypro Orange (a
250-fold dilution of the 5,000
 stock solution purchased), 0.76
 EMSA
buffer (7.6 mM Tris-acetate [pH 7.4], 0.76 mM K-EDTA, 38 mM KCl, and
0.76 mM DTT), 4% DMSO, and either no SE-1 or 80 M SE-1. The
reactions were carried out in low-profile 0.1-ml PCR 8-tube strips with
optically clear flat caps (USA Scientific) in a StepOnePlus real-time PCR
system (Applied Biosystems), with heating from 25 to 99°C in increments
of 0.8°C. The data were analyzed using the Boltzmann sigmoidal model in
GraphPad Prism software (GraphPad). Data points before and after the
fluorescence intensity minimum and maximum, respectively, were ex-
cluded from fitting. The values for Tm (Tm changes) are averages for
three independent experiments with two replicates in each experiment.
Results of a single representative experiment are shown.
Shigella virB-lacZ reporter gene assays. Colonies of S. flexneri strain
BS536 that were red on TSA plates containing Congo red were grown
overnight in Luria-Bertani broth at 30°C to maintain low basal expression
from the virB promoter. The overnight-grown cultures were diluted 1:100
into 10 ml of the same medium with either 0.3% DMSO or different
concentrations of SE-1 dissolved in DMSO (final concentration, 0.3%
DMSO). Cultures were grown at 37°C in a shaking incubator to an OD600
of 0.4, centrifuged to pellet the cells, and then resuspended in Z buffer
for a 2-fold concentration of the cells (63). Control cultures were grown at
30°C, a temperature at which virF expression is not induced (36), to illus-
trate the basal level of expression from the virB promoter region. -Ga-
lactosidase assays were performed as described previously using the
method of Miller (63), except that incubation with the substrate o-nitro-
phenyl--D-galactopyranoside (ONPG) was carried out at room temper-
ature. Activities are presented as percentages of the activity of the unin-
hibited, DMSO-only control sample. Three independent assays were
performed, with two replicates in each assay. Error bars in figures repre-
sent the standard errors of the means.
Shigella gene expression analysis. Real-time quantitative reverse
transcription-PCR (qRT-PCR) was performed to test the effects of SE-1
on the expression of the VirF-regulated genes virB, icsA, icsB, and ipaB.
The gapA and rrsA transcripts were used as internal controls. These are
constitutively expressed Shigella genes commonly used to normalize
mRNA levels (72–74). S. flexneri strain SME4331, which carries a null
mutation in ipgD, was grown at 30°C overnight in TSB with ampicillin and
was then diluted into the same medium to an OD600 of 0.1, and 1-ml
aliquots were further grown at 30°C (with DMSO only) or at 37°C (with
SE-1 at 20 or 40 M, or with DMSO only; in all cases, the concentration of
DMSO was 0.3%). Cells were grown to an OD600 of 1.0 (2.5 h), and RNA
was isolated using an RNeasy MinElute cleanup kit (Qiagen, German-
town, MD); DNA contamination was eliminated by using a Turbo DNase
kit (Ambion, Austin, TX). cDNA was synthesized by random priming
using a cDNA reverse transcription kit (Applied Biosystems, Foster City,
CA). Primers (Table 2) were tested for PCR specificity using a genomic
DNA template to ensure a single amplicon of the expected size for each
primer pair and were validated using 5-fold dilutions of cDNA (2,000 to
0.0256 ng) to ensure a linear plot of the cycle threshold (CT) versus cDNA
concentration. Validated primer sets were used to test mRNA profiles
with reaction mixtures that contained 10 ng of cDNA, 10 l of SYBR green
master mix (Applied Biosystems), specific primers (0.5 M each), and
water to a final volume of 20 l, using a StepOnePlus real-time PCR
system (Applied Biosystems). The data were analyzed using the 2CT
method, as described previously (75), and also by Applied Biosystems
real-time analysis software. The data analyzed by the 2CT method are
reported; however, the two analyses produced comparable results. In
brief, CT values [calculated as (CT for the target in the presence of
SE-1  CT for the internal control in the presence of SE-1)  (CT for the
target in the absence of SE-1  CT for the internal control in the absence
of SE-1)] were obtained separately for each sample relative to two internal
controls, gapA and rrsA. The CT values for each sample relative to the
two internal controls were averaged and were then used to calculate the
relative expression levels (2CT). As a control, we also normalized each
internal control to the other internal control. Examples of data and cal-
culated values are shown in Table S1 in the supplemental material. Con-
trol reactions used templates generated without reverse transcriptase to
ensure low genomic DNA contamination. To ensure that products were
not likely to be due to primer dimer artifacts, additional control reactions
were performed in which the reaction mixtures contained primers alone
(no template).
Shigella growth curves. The S. flexneri ipgD-null strain (SME4331)
was grown overnight at 30°C and was then diluted to an OD600 of 0.1 in
TSB supplemented with ampicillin. SE-1 was diluted in DMSO and either
was not added to the SME4331 cultures (0.3% DMSO only) or was added
TABLE 2 Primers for qRT-PCR
Gene Forward primer (5=–3=) Reverse primer (5=–3=)
Amplicon
size (bp)
virB GGAAGGGAGATTGATGGTAG GAACTTCAAGATCTGCTCCTGC 84
icsA CTTTCGGGTACTCAAGAAC GAGAAAGTCCATCAACAGG 76
icsB CTCAATTCAACACTCTTTCACAG GGCTGTACCGATGCCATGAAAACG 82
ipaB CTGCATTTTCAAACACAGC GAGTAACACTGGCAAGTC 78
gapA GTTCTGACATCGAGATCGTTGC GTGAGTGGAGTCATATTTCAGCATG 83
rrsA AACGTCAATGAGCAAAGGTATTAA TACGGGAGGCAGCAGTGG 140
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at a final concentration of 20 or 40 M with 0.3% DMSO. These cultures
were grown at 37°C in 24-well plates containing 1.2 ml of each sample in
the temperature-controlled chamber of a PowerWave XS plate reader
equipped with KC4 data analysis software (BioTek Instruments). Bacterial
growth was continued at 37°C for 8 h with shaking, and the OD600 was
monitored every 5 min for growth curves (20-min time intervals were
plotted).
Shigella invasion assays. The S. flexneri ipgD-null (SME4331) and
mxiH-null (SB116) (6) mutant strains were grown overnight at 30°C and
were then diluted to an OD600 of 0.1 into TSB plus ampicillin. SE-1 (in
DMSO) either was not added to the cultures (0.3% DMSO only) or was
added at a final concentration of 20 or 40 M SE-1 with 0.3% DMSO.
These cultures and SB116 (no SE-1) were grown at 37°C in 24-well plates
(each with 1.2 ml) in the temperature-controlled chamber of a Power-
Wave XS plate reader (BioTek Instruments). Bacterial growth was contin-
ued at 37°C with shaking, and the OD600 was monitored every 15 min. A
separate sample of SME4331 was grown at 30°C. L-929 cells (mouse fibro-
blasts, used previously for Shigella invasion assays [76–79]) that had been
grown overnight to 90% confluence in 24-well plates were washed three
times with 1 ml of RPMI medium each (without FBS or antibiotics), and
the final wash was removed by aspiration. (All L-929 incubation steps
were carried out at 37°C under a 5% CO2 humidified atmosphere.) When
the OD600 of the bacterial cultures reached 1.0 (2.5 h), samples were
diluted 100-fold in prewarmed RPMI medium (without FBS or antibiot-
ics), and then 300 l was added to each monolayer of L-929 cells, for a
multiplicity of infection of roughly 20. In a control sample, 40 M SE-1
and bacteria grown at 37°C without SE-1 were added at the same time to
L-929 cells. The 24-well plate was centrifuged (2,000 
 g) for 5 min at
room temperature to initiate bacterium-host cell contact, incubated for
45 min at 37°C, washed three times with 1 ml RPMI medium containing
50 g/ml gentamicin (or without gentamicin for the control), and incu-
bated at 37°C for 2 h. Cells were again washed three times with 1 ml RPMI
medium and were then lysed in 100 l of phosphate-buffered saline (PBS)
(Mediatech) containing 0.1% Triton X-100 (Promega, Madison, WI) for
10 min at room temperature. The 100-l lysates from the gentamicin-
treated and untreated L-929 cells were mixed with 400 l TSB, and 100 l
of further dilutions (1:50 and 1:250) was plated onto TSB agar containing
ampicillin. Plates were incubated overnight at 37°C, and colonies were
counted. The number of colonies obtained from gentamicin-treated sam-
ples was divided by the number of colonies from control samples without
gentamicin, and the quotient was multiplied by 100 to calculate the inva-
sion index, as described previously (80).
alamarBlue assays were performed as a control to test whether SE-1
had any impact on the metabolic activity of the host cells, as follows. L-929
cells were seeded into 96-well plates and were grown overnight to 90%
confluence. SE-1 was serially diluted in RPMI medium supplemented
with 10 g/ml gentamicin and 5% FBS, added to the wells, and incubated
at 37°C for 3 h. Cells were washed with 200 l Hanks’ balanced salt solu-
tion (Mediatech) and were incubated with 200 l RPMI medium (with-
out phenol red) containing 10% alamarBlue (also known as resazurin;
Invitrogen, Grand Island, NY). Following 8 h of incubation at 37°C, the
absorbance was measured at 570 nm and 600 nm using a PowerWave XS
plate reader, and the metabolic activity of the cells (as a percentage of that
of untreated controls) was calculated using the following formula pro-
vided by the manufacturer: [(117,216 
 A570)  (80,586 
 A600)]/
[(117,216 
 A570=)  (80,586 
 A600=)] 
 100, where A is the absorbance
of test wells and A= is the absorbance of positive-control wells (mock
infection) (81).
RESULTS
SE-1 inhibited VirF activation of a virB-lacZ fusion in E. coli.
The small molecule SE-1 (Fig. 1A) was previously found to inhibit
DNA binding and transcription activation by the E. coli AraC fam-
ily proteins RhaS and RhaR (60). Given that our findings indicated
that SE-1 interacted with the relatively conserved DNA-binding
domains of these AraC family proteins, we tested whether it might
also inhibit VirF, an AraC family activator required for virulence
in Shigella. SE-1 inhibition of transcription activation by VirF was
first tested using cell-based assays in E. coli. We performed -ga-
lactosidase assays in the absence or presence of the inhibitor with
a nonpathogenic strain of E. coli that carried a single copy of the
lacZ reporter gene under the control of the virB promoter (virB-
lacZ) in the chromosome (see Fig. S1 [top] in the supplemental
material) and a plasmid with IPTG-inducible expression of VirF.
A control strain carried plasmid-encoded LacI and the lacZ re-
porter gene under the control of the synthetic, LacI-repressible hts
promoter (hts-lacZ) (60) (see Fig. S1, bottom). This control strain
served to distinguish the inhibition of overall transcription or
-galactosidase activity, for example, from selective inhibition of
transcription activation by VirF. IPTG was added to the cells (to
induce VirF expression or to release LacI from repressing hts-lacZ)
at the same time as the inhibitor. Thus, -galactosidase was main-
tained at an uninduced level until the inhibitor was added, and it
was not necessary to wait for the decay of preformed -galactosi-
dase to detect inhibition. The expression of lacZ from uninduced
and induced controls was set to 0% and 100%, respectively, thus
normalizing the effect of the inhibitor on the VirF-activated fu-
sion and the LacI-repressed fusion.
SE-1 inhibition of transcription activation by VirF was pre-
dicted to decrease lacZ expression from virB-lacZ with little or no
effect on hts-lacZ expression. In contrast, a decrease in lacZ ex-
pression from both virB-lacZ and hts-lacZ would indicate that
inhibition was not specific for VirF. We found that SE-1 showed
substantially greater, dose-dependent inhibition of the VirF-acti-
vated lacZ fusion than of the LacI-repressed fusion (Fig. 1B). The
IC50 of SE-1 for expression from the VirF-activated fusion was 8
M. This is a typical potency for a hit from a high-throughput
screen (low M to high nM potency range) that has not yet been
chemically optimized (82) and a higher potency than the IC50 of
30 M found in similar assays with RhaS (60). As in the previous
report in which we used hts-lacZ as a control (60), there was also
some nonspecific inhibition of LacZ expression from the LacI-
repressed fusion at higher doses of SE-1. Overall, these cell-based
assays suggest that SE-1 inhibits transcription activation by VirF,
at least in E. coli, with reasonable selectivity.
SE-1 did not impact the growth of E. coli. Bacterial growth
assays were performed to ensure that the observed inhibition of
VirF activation could not be attributed to toxicity for the strains of
E. coli used in the cell-based reporter assays. Strains carrying the
VirF-activated and LacI-repressed fusions were grown for 8 h at
37°C in the same minimal medium used for the in vivo dose-
response assays. We detected no effect of SE-1 on the growth of
either strain, indicating that the inhibition observed in the whole-
cell assays could not be attributed to effects on cell growth (see Fig.
S3 in the supplemental material). As a control, we tested whether
0.3% DMSO (the solvent for SE-1) had any impact on the growth
rates of these strains of E. coli and found that it did not (see Fig.
S3). The finding that the concentrations of SE-1 tested had no
detectable effects on bacterial growth rates further supports the
conclusion that SE-1 exhibits selectivity for VirF inhibition.
SE-1 inhibited in vitro DNA binding by VirF. Electrophoretic
mobility shift assays (EMSAs) were performed to investigate
whether, as with RhaS and RhaR (60), SE-1 inhibits DNA binding
by purified VirF protein (MBP-VirF). The VirF protein was puri-
fied using amylose affinity chromatography, and the DNA tested
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included the VirF binding site sequence from the virB promoter
region. Our results indicate that SE-1 was able to fully inhibit DNA
binding by VirF in a dose-dependent manner (Fig. 2). The con-
centration of SE-1 required for half-maximal inhibition of DNA
binding was higher than the IC50 for the cell-based assays. How-
ever, it was not possible to calculate an accurate IC50 from the
DNA binding assays due to limitations of the sensitivity of the
detection method, the solubility of SE-1, and residual aggregation
of the purified VirF protein. We showed previously that SE-1 did
not inhibit DNA binding by the LacI protein or CRP (60). LacI
and CRP are not members of the AraC family; each is a founding
member of its own protein family (83–85). Overall, our EMSA
results indicate that SE-1 can block the ability of VirF to bind to its
specific DNA site.
SE-1 binds directly to VirF. The finding that SE-1 blocked
DNA binding by VirF but not by the non-AraC family proteins
LacI and CRP suggested that SE-1 might bind directly to VirF. (At
least in the simplest case, SE-1 binding to DNA would be expected
to inhibit DNA binding by any protein tested.) To test the hypoth-
esis that SE-1 binds to VirF, we performed thermal shift assays (69,
70) using the dye Sypro Orange. In this assay, there is an increase
in fluorescence intensity upon the binding of Sypro Orange to the
exposed hydrophobic residues of a thermally unfolding protein.
The unfolding transition allows calculation of the protein’s Tm
and any melting temperature changes (Tm) due to the increased
protein stability imparted by ligand binding.
Using the thermal shift assay, we found that the addition of 80
M SE-1 increased the Tm of VirF (1 M) by 0.61°C (0.09) (Fig.
3A). While this appears to be a relatively small change in melting
temperature, the following evidence supports the conclusion that
this likely indicates binding of SE-1 to VirF. Pantoliano et al. (69)
used a melting temperature change cutoff of 0.5°C or greater to
indicate ligand binding to the target protein after testing more
than 100 different proteins. Further, the Tm for VirF with 80 M
SE-1 is much greater than that found with 40 M SE-1 (0.15°C 
0.04 [data not shown]), suggesting that VirF is likely not saturated
with SE-1 at 80 M and that a higher Tm would likely be found if
we could test higher concentrations of SE-1 (86). Finally, multiple
reports of Tm values similar to ours have been validated as indi-
cating true binding to a protein (69, 87–89).
Since our VirF protein is a fusion with MBP, we tested an
unrelated MBP fusion protein (MBP-NS1-NTD) to determine
FIG 2 SE-1 inhibition of in vitro DNA binding by VirF. (A) A representative
EMSA gel image. The black triangle represents decreasing concentrations of
SE-1, from 1.3 mM to 10 M, with serial 2-fold dilutions. (B) The binding of
purified VirF to a DNA fragment containing the VirF binding site from the
virB promoter was assayed using EMSAs with the inhibitor SE-1 at concentra-
tions from 10 to 650 M (serial 2-fold dilutions). DNA and protein were used
at final concentrations of 2 and 300 nM, respectively. The DNA shifted (bound
by VirF) was quantified, and the value at the lowest concentration of SE-1 was
set to 100%. Results are averages for three independent replicates.
FIG 3 Thermal shift assay showing that SE-1 binds to VirF protein. The ther-
mal denaturation of MBP-VirF (A) and MBP-NS1-NTD (B) was measured
using the dye Sypro Orange. Assays were carried out in the absence (DMSO
only) or presence of 80 mM SE-1. Readings were taken from 25 to 99°C. Only
the relevant portions of the curves are shown. Results of a single experiment
(representative of three independent assays with two replicates each) are
shown.
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whether SE-1 bound to MBP. NS1 is a poxvirus protein that is not
a member of the AraC family. MBP-NS1-NTD showed only a
0.15°C (0.06) change in melting temperature, and the melting
curve with SE-1 was not well separated from that with the DMSO-
only control (Fig. 3B), suggesting that SE-1 did not bind to MBP.
We conclude that SE-1 binds directly to VirF and hypothesize that
this binding is responsible for the inhibition of DNA binding, and
thus of transcription activation, by VirF.
SE-1 inhibited activation of a virB-lacZ fusion by VirF in Shi-
gella. Our cell-based assays in E. coli indicated that SE-1 was able
to effectively inhibit activation by VirF at the virB promoter re-
gion. To test whether similar inhibition occurred in Shigella, we
assayed the effect of SE-1 on VirF activity in an S. flexneri strain
carrying a virB-lacZ fusion. -Galactosidase assays were per-
formed on bacterial cultures grown at 37°C in the absence or pres-
ence of varying concentrations of the inhibitor. Our results show a
dose-dependent inhibition of virB-lacZ expression, with a maxi-
mum inhibition of 2-fold at 40 M SE-1 (Fig. 4). This inhibition
was most likely due to inhibition of VirF activity. We calculated an
IC50 of approximately 30 M, somewhat higher than the IC50 of 8
M achieved in E. coli. S. flexneri samples grown in 80 M SE-1
were not analyzed, because they exhibited growth defects. Shigella
cultures grown at 30°C in the absence of SE-1 were used to identify
the basal level of virB-lacZ expression (36, 38, 40, 41). These as-
says, like the cell-based assays in E. coli, indicate that SE-1 inhibits
transcription activation by VirF at the virB-lacZ promoter region
and, further, provide evidence that SE-1 is effective in Shigella.
SE-1 reduced VirF-regulated virulence gene expression in
Shigella. Our next goal was to test the impact of SE-1 on the
expression of other VirF-regulated genes in Shigella. Previous re-
ports have shown that the icsA and virB genes are direct targets of
VirF activation at 37°C (36). VirB, in turn, activates the expression
of many operons that play a crucial role in Shigella pathogenesis
(37). Thus, any compound that inhibits transcription activation
by VirF should also affect the expression levels of genes that either
directly or indirectly require VirF for their expression. To test this
hypothesis, we used qRT-PCR to quantify the mRNA levels of two
genes that are direct targets of VirF, icsA and virB, and two that are
indirect targets of VirF, icsB and ipaB (both directly activated by
VirB) (37). S. flexneri samples were grown to an OD600 of 1.0 in
the absence or presence of two different concentrations of SE-1
(20 M and 40 M), and the mRNA levels for each of these genes
were quantified. S. flexneri samples grown at 30°C in the absence
of SE-1 were included to illustrate the basal expression levels of
these genes. The results were normalized to those for the gapA
(encoding glyceraldehyde-3-phosphate dehydrogenase) and rrsA
(encoding 16S rRNA) genes, two constitutively expressed genes
commonly used as qRT-PCR controls in Shigella (72–74).
Our qRT-PCR results showed that the icsA expression level
remained essentially unchanged at 20 M inhibitor but was sig-
nificantly reduced (P  0.05) at 40 M inhibitor (Fig. 5A). Ex-
pression of virB, another direct target of VirF, decreased signifi-
cantly with increasing concentrations of the inhibitor, with a
maximal inhibition of 2-fold at 40 M SE-1 (P  0.05) (Fig.
5B). Expression of icsB, an indirect target of VirF (55, 56), showed
a significant 2-fold reduction at 40 M SE-1 (P  0.05) (Fig. 5C).
The greatest inhibition was detected for the expression of ipaB,
another indirect target of VirF, which was reduced as much as
4-fold at 40 M inhibitor (P  0.05) (Fig. 5D). As a control, we
normalized each of the internal control genes relative to the other
internal control gene. We found that there was no decrease in the
expression of either control gene with 40 M SE-1 (see Fig. S4 in
the supplemental material), arguing that SE-1 did not result in a
global decrease in gene expression. Together, our data demon-
strate that SE-1 is capable of reducing the expression of at least
four VirF-regulated virulence-associated genes in Shigella, pre-
sumably through its inhibition of transcription activation by VirF.
SE-1 inhibited the invasion of host cells by Shigella. Our
qRT-PCR experiments with SE-1 showed a decrease in the expres-
sion of virulence genes in Shigella. In order to test the impact of
this decrease in virulence gene expression on the ability of Shigella
to invade host cells, invasion assays (80) were performed with the
mouse fibroblast line L-929. L-929 cells have been used previously
to study the invasion of host cells by Shigella (76–79). The S. flex-
neri strain used in the assays was an ipgD-null strain that has
hemolysis and invasion properties similar to those of the wild type
but is safer to work with due to its reduced ability to cause human
infection (90–92). The cells were grown at 30°C overnight and
were then diluted and grown at 37°C (to induce the expression of
VirF-regulated genes) in the presence or absence of various con-
centrations of SE-1. In addition, S. flexneri strain SB116 (a mxiH-
null mutant) was used as a negative control for invasion, since it
does not form a T3SS needle and thus is unable to invade host cells
(6). S. flexneri grown at 30°C was used as a second negative control
for invasion, since these bacteria have reduced expression of VirF
and VirB and thus are defective for invasion of host cells (37). Our
results showed a dose-dependent decrease in the invasion of L-929
cells by Shigella upon addition of SE-1 (Fig. 6A). SE-1 resulted in
invasion decreases of 1.7-fold at 20 M and 3-fold at 40 M from
levels with no inhibitor. As expected, both of the negative controls
(wild-type S. flexneri grown at 30°C and the mxiH-null strain)
showed substantially decreased invasion relative to that of the
wild-type strain grown at 37°C. As in our growth assays with E.
coli, we found that 0.3% DMSO did not detectably slow the
growth of Shigella (data not shown), and SE-1 resulted in no de-
tectable decrease in the Shigella growth rate at concentrations as
high as 40 M (see Fig. S5 in the supplemental material).
Overall, our results suggest the hypothesis that SE-1 inhibits
Shigella invasion by decreasing the expression of the genes in the
VirF regulon, including the genes that encode the T3SS. Thus,
FIG 4 Inhibition by SE-1 of in vivo VirF activation in Shigella. -Galactosidase
(LacZ) activity from a virB-lacZ transcriptional fusion in Shigella, with native
VirF expression, was assayed at the indicated concentrations of the inhibitor
SE-1. Activity in the absence of SE-1 was set to 100% and corresponded to
approximately 3,000 Miller units. The result for Shigella grown at 30°C illus-
trates the basal expression of virB-lacZ. Results are averages for three indepen-
dent experiments with two replicates each.
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Shigella grown under inducing conditions (37°C) without SE-1
would not be inhibited by the addition of SE-1 unless growth with
SE-1 was continued for a period sufficient for the loss of pre-
formed VirF-regulated gene products, such as the T3SS. To test
this hypothesis, Shigella bacteria were grown at 37°C in the ab-
sence of the inhibitor, and then Shigella and SE-1 were added to
L-929 cells at the same time. This control also tested whether SE-1
had any impact on the L-929 cells that affected invasion by Shi-
gella. Our result suggests that the inhibition of invasion by SE-1
was likely not due to posttranscriptional effects on Shigella or to
effects on the eukaryotic cells, since this control sample invaded to
the same extent as Shigella grown in the absence of the inhibitor
(Fig. 6A). Overall, our results support the hypothesis that SE-1
decreases the expression of VirF-regulated virulence genes and
that this decrease, in turn, results in a reduction in the ability of
Shigella to invade host cells.
In principle, it is possible that the decrease in the level of inva-
FIG 5 Inhibition by SE-1 of the expression of VirF-regulated virulence genes in
Shigella. qRT-PCR was used to determine the relative quantities (RQ) of icsA (A),
virB (B), icsB (C), and ipaB (D) expressed in Shigella grown at 30°C (without SE-1)
and at 37°C (without or with 20 or 40 M SE-1). RNA levels were normalized to
those of two constitutively expressed genes, gapA and rrsA. RNA levels were set to
1 in the absence of SE-1. The results for Shigella grown at 30°C illustrate the basal
expression of each gene. Error bars represent the standard errors of the means
calculated from three independent replicates. The significance of values for inhib-
itor-treated bacteria was calculated using a nonparametric Mann-Whitney test; P
values less than 0.05 were considered significant (*). Results are averages for three
independent experiments with one replicate each.
FIG 6 Inhibition by SE-1 of invasion of host cells by Shigella but not of host
cell metabolism. (A) The index of invasion of L-929 (mouse fibroblast) cells by
Shigella was determined by a gentamicin protection assay. Cultures were
grown in the absence or presence of SE-1 (20 M or 40 M). An mxiH-null
Shigella strain (SB116) and an ipgD-null strain (SME4331) grown at 30°C were
used as negative controls for invasion. As an additional control, 40 M SE-1
and Shigella grown at 37°C without the inhibitor were added to L-929 cells at
the same time to test the effect of the inhibitor on invasion by a Shigella strain
with a preformed T3SS and on host cells. (B) alamarBlue assays to test the
effect of SE-1 (at the indicated concentrations) on the metabolic activity (via-
bility) of L-929 cells. The absorbance level in the absence of the inhibitor and
the presence of DMSO was set to 100%. Assays for both panels were performed
in triplicate, and error bars represent the standard errors of the means.
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sion of L-929 cells by Shigella was the result of SE-1 compromising
host cellular processes and thereby decreasing the viability of the
host cells. To test this possibility, the effect of SE-1 on the viability
of L-929 cells was assayed using an alamarBlue cell viability assay
(Invitrogen, Grand Island, NY). The alamarBlue assay is a fluores-
cence-based assay of the viability of host cells based on their met-
abolic activity (93). During our invasion assays, the L-929 cells
were exposed only to SE-1 concentrations of 0.2 and 0.4 M, due
to dilution of the SE-1-containing Shigella culture. Our alamar-
Blue assays indicated that these concentrations of SE-1 did not
detectably decrease the viability of L-929 cells (Fig. 6B). In fact, a
100-fold-higher concentration (40 M) had no effect on host cell
viability. These results support the hypothesis that the effect of
SE-1 on invasion by Shigella was not an indirect effect on L-929
cell viability. Further, the results provide evidence that SE-1 did
not have detectable toxicity for the L-929 cells at concentrations as
high as 40 M.
DISCUSSION
Many bacterial pathogens require AraC family transcriptional
regulators to cause disease (24–29). VirF, one such AraC family
regulator, activates the expression of a cascade of virulence genes
required for successful infection by Shigella (43, 44). Thus, inhib-
itors that block transcription activation by VirF (preferably with-
out detrimental effects on the growth of the bacteria) have poten-
tial to be developed into novel antimicrobial agents. The
nonessential nature of VirF may reduce the probability that Shi-
gella will develop resistance to VirF inhibitors (22, 32–34). A high-
throughput screen performed by a different group identified sev-
eral inhibitors of VirF activation of virB-lacZ reporter expression;
however, the mechanisms of inhibition and further effects on Shi-
gella infections were not tested (59). We recently identified an
inhibitor, SE-1, that inhibited transcription activation by the
AraC family proteins RhaS and RhaR by blocking their ability to
bind to DNA (60). In the present study, we tested SE-1 for inhibi-
tion of VirF and of VirF-dependent Shigella virulence.
Using a cell-based reporter gene assay to test the ability of SE-1
to inhibit transcription activation by the VirF protein, we found
that SE-1 decreased virB-lacZ reporter fusion expression in an E.
coli strain with plasmid-expressed VirF. The inhibition was dose
dependent, with an IC50 of approximately 8 M, suggesting that
SE-1 inhibited transcription activation by VirF. An initial indica-
tion that this inhibition was selective for VirF activity was the
finding that SE-1 inhibited lacZ expression from a control fusion
(hts-lacZ) substantially less than it inhibited VirF-dependent lacZ
expression. The strains carrying the VirF-dependent and control
lacZ fusions showed no detectable growth defects in the presence
of SE-1, indicating that SE-1 did not have general toxicity for these
E. coli strains at the concentrations tested.
We showed previously that the inhibition of the AraC family
activators RhaS and RhaR by SE-1 involved blocking their binding
to DNA (60). Thus, we tested SE-1 for inhibition of the binding of
purified VirF protein to DNA carrying a VirF binding site, and we
found that SE-1 was able to fully inhibit DNA binding by VirF. We
also showed previously that SE-1 did not inhibit DNA binding by
two proteins that are not related to the AraC family, LacI and CRP
(60), suggesting that SE-1 is selective for AraC family proteins.
Our thermal shift assay results suggest that SE-1 can bind directly
to the VirF protein. Overall, our results support the hypothesis
that the mechanism of action of SE-1 inhibition involves selec-
tively blocking DNA binding by VirF by directly binding to the
protein.
We next tested inhibition by SE-1 in Shigella. Initially, we
tested SE-1 for the ability to inhibit endogenously expressed VirF
in a Shigella strain carrying a virB-lacZ reporter construct. As in E.
coli, we observed dose-dependent inhibition of VirF activation of
virB-lacZ in Shigella. In addition, Shigella grown in the presence of
SE-1 showed decreases both in the transcription (assayed by qRT-
PCR) of genes that are directly activated by VirF (virB, icsA) and in
the transcription of genes that are directly activated by VirB (in-
direct VirF targets; icsB, ipaB). In these experiments, we observed
decreases of as much as 2- to 4-fold in the expression of these
VirF-dependent genes; the values were consistent with those ob-
tained in the virB-lacZ assays in Shigella. However, the same con-
centration of SE-1 resulted in lower levels of inhibition in Shigella
than in E. coli, suggesting differences in the uptake, efflux, and/or
stability of SE-1 between these two bacteria. Alternatively, as with
many commonly used antibiotics (94), there may be differences in
sensitivity to SE-1 between organisms grown in minimal medium
(used for E. coli) and those grown in rich medium (used for Shi-
gella).
Several findings argue that the decreases in virB-lacZ, virB, icsA,
icsB, and ipaB expression in Shigella were due to inhibition of VirF
activity and not to a global decrease in gene expression in the
presence of SE-1. First, there was no detectable decrease in the
growth rate of Shigella in the presence of as much as 40 M SE-1,
whereas global decreases in gene expression of a comparable mag-
nitude would be expected to affect the growth rate. Second, the
qRT-PCR results were normalized to results for two different in-
ternal-control genes (which would be expected to exhibit de-
creased expression if there was a global decrease in gene expres-
sion). Normalization of each of the internal-control genes relative
to the other showed that there was no significant change in the
expression of the control genes in the presence of 40 M SE-1.
Finally, the magnitudes of inhibition of virB expression by SE-1
detected in the virB-lacZ assays and the qRT-PCR assays were
essentially the same, indicating that the normalization of the qRT-
PCR results to those for the internal controls did not alter the
extent of the inhibition (as would have been expected if expression
of the internal control genes was also inhibited).
Finally, we investigated the effect of SE-1 on the ability of Shi-
gella to invade mouse fibroblasts (L-929 cells) in tissue culture. A
dose-dependent decrease in invasion was observed, with a maxi-
mum inhibition of 70% at 40 M inhibitor. This inhibition re-
quired preincubation of Shigella with SE-1, in agreement with the
hypothesis that SE-1 did not destabilize preassembled T3SS or
other Shigella virulence components, inhibit posttranscriptional
processes in Shigella, or cause cytotoxicity to L-929 cells at the
concentrations tested. The latter notion is further supported by
the finding that at the same concentrations, SE-1 did not result in
a detectable decrease in the metabolism of L-929 cells in alamar-
Blue assays.
Overall, our results suggest a model in which SE-1 inhibits
VirF-dependent activation of the transcription of Shigella viru-
lence genes, including at least icsA, virB, icsB, and ipaB. The de-
crease in invasion we detected is consistent with, and can be at-
tributed to, the effect of decreased expression of these virulence
genes in the VirF regulon. The 2- to 4-fold decreases in the expres-
sion of these genes appear to be sufficient to decrease the level of
Shigella invasion by 70% from that without the inhibitor. The ipaB
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gene exhibited the largest decrease in expression, 4-fold, suggest-
ing that a reduction in IpaB expression may be associated with
reduced invasion in the presence of SE-1. This is a reasonable
hypothesis given the central role IpaB plays in Shigella invasion.
IpaB is a component of the translocon pores in the host cell mem-
brane (51), which enable the translocation of Shigella effectors
into host cells (54), ultimately modulating host cell cytoskeletal
dynamics and leading to bacterial invasion (52). In addition, only
a subset of the VirF-regulated virulence genes that are required for
invasion were assayed (43, 44); thus, decreased expression of other
genes likely also contributed to the invasion defects.
We have now shown that SE-1 selectively inhibits DNA bind-
ing by three different AraC family proteins (60). The VirF protein
shares only about 15% amino acid sequence identity and 40%
similarity with RhaS and RhaR (the pairwise RhaS-VirF and
RhaR-VirF comparisons are nearly the same) (see Fig. S6 in the
supplemental material). Given our prior finding that SE-1 blocks
transcription activation by the RhaS DBD to at least the same
extent as that by the full-length RhaS protein (60), we hypothesize
that the VirF DNA-binding domain is the likely site of action of
SE-1. The sequence similarities in this domain are somewhat
higher than those of the full-length proteins but are still relatively
low: the VirF DBD shares about 22% identity and 52% similarity
with the RhaS and RhaR DBDs. This finding supports the hypoth-
esis that SE-1 may bind to a relatively conserved region of AraC
family DNA-binding domains. We cannot rule out the possibility
that SE-1 inhibits other AraC family activators in addition to VirF
in Shigella; however, it is likely that inhibition of VirF would exert
the greatest impact on genes in the VirF regulon and on host cell
invasion. In addition to the inhibitory effects of SE-1 on VirF from
the S. flexneri strains used in our work, SE-1 may also be effective
against other pathogenic Shigella species (Shigella dysenteriae, S.
sonnei, and S. boydii), since VirF is the master virulence regulator
in all these species and shares 100% identity (1).
In conclusion, we have identified SE-1 as an inhibitor of tran-
scription activation by VirF by using cell-based reporter gene as-
says, DNA binding assays, and invasion assays. SE-1 is noncyto-
toxic toward the eukaryotic cells tested (at concentrations as high
as 40 M), is nonbactericidal toward E. coli and Shigella (at con-
centrations as high as 40 M), and has potential to be developed
into a novel antibacterial agent. However, SE-1 does show evi-
dence of nonspecific inhibition at higher concentrations (partial
inhibition of hts-lacZ at higher concentrations and inhibition of
Shigella growth at 80 M SE-1), and its current potency is not
sufficient for therapeutic applications. Thus, chemical optimiza-
tion of SE-1 will be needed to improve both its potency and its
specificity before it can be considered a lead compound for further
development. In addition, once Shigella cells invade host epithelial
cells, they are able to spread directly from cell to cell and are no
longer exposed to the extracellular environment (95). We do not
know whether SE-1 can penetrate host cells; however, it is known
that intracellular Shigella requires VirF for growth, viability, and
cell-to-cell spread (96). Therefore, if SE-1 (or a chemically opti-
mized analog) were able to penetrate host epithelial cells, it might
reduce growth and cell-to-cell spread and increase host-mediated
killing of Shigella bacteria that have already invaded host cells. It is
also not yet known whether SE-1 inhibits the activity of MxiE, an
AraC family activator that regulates the expression of T3SS effec-
tors after invasion and is required for Shigella virulence in an an-
imal model (50).
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